首页> 外文期刊>Nanotechnology >Novel rivaroxaban-loaded poly(lactic-co-glycolic acid)/poloxamer nanoparticles: preparation, physicochemical characterization, in vitro evaluation of time-dependent anticoagulant activity and toxicological profile
【24h】

Novel rivaroxaban-loaded poly(lactic-co-glycolic acid)/poloxamer nanoparticles: preparation, physicochemical characterization, in vitro evaluation of time-dependent anticoagulant activity and toxicological profile

机译:新型亚甲氧基甲烷加载聚(乳酸二乙醇酸)/泊洛沙姆纳米粒子:制备,物理化学表征,体外评估时间依赖性抗凝活性和毒理学概况

获取原文
获取原文并翻译 | 示例
           

摘要

Rivaroxaban (RXB), an oral direct factor Xa inhibitor, presents innovative therapeutic profile. However, RXB has shown adverse effects, mainly due to pharmacokinetic limitations, highlighting the importance of developing more effective formulations. Therefore, this work aims at the preparation, physicochemical characterization and in vitro evaluation of time-dependent anticoagulant activity and toxicology profile of RXB-loaded poly(lactic-co-glycolic acid) (PLGA)/ poloxamer nanoparticles (RXBNps). RXBNp were produced by nanoprecipitation method and physicochemical characteristics were evaluated. In vitro analysis of time-dependent anticoagulant activity was performed by prothrombin time test and toxicological profile was assessed by hemolysis and MTT reduction assays. The developed RXBNp present spherical morphology with average diameter of 205.5 +/- 16.95 nm (PdI 0.096 +/- 0.04), negative zeta potential (-26.28 +/- 0.77 mV), entrapment efficiency of 91.35 +/- 2.40%, yield of 41.81 +/- 1.68% and 3.72 +/- 0.07% of drug loading. Drug release was characterized by an initial fast release followed by a sustained release with 28.34 +/- 2.82% of RXB available in 72 h. RXBNp showed an expressive time-dependent anticoagulant activity in human and rat blood plasma and non-toxic profile. Based on the results presented, it is possible to consider that RXBNp may be able to assist in the development of promising new therapies for treatment of thrombotic disorders.
机译:利伐沙班(RXB)是一种口服直接因子Xa抑制剂,具有创新的治疗特点。然而,RXB已显示出副作用,主要是由于药代动力学限制,这突出了开发更有效配方的重要性。因此,本研究旨在制备RXB负载聚乳酸-羟基乙酸共聚物(PLGA)/泊洛沙姆纳米粒(RXBNps),并对其进行理化表征和体外时间依赖性抗凝活性和毒理学评价。采用纳米沉淀法制备了RXBNp,并对其理化性质进行了评价。通过凝血酶原时间试验进行时间依赖性抗凝活性的体外分析,并通过溶血和MTT还原试验评估毒理学特征。研制的RXBNp呈球形,平均直径为205.5+/-16.95nm(PdI 0.096+/-0.04),zeta电位为负(-26.28+/-0.77mV),包封率为91.35+/-2.40%,产率为41.81+/-1.68%,载药量为3.72+/-0.07%。药物释放的特点是先快速释放,然后在72小时内持续释放28.34+/-2.82%的RXB。RXBNp在人和大鼠血浆中表现出明显的时间依赖性抗凝活性和无毒性。基于所提出的结果,有可能认为RXBNP可能能够帮助开发有前途的治疗血栓形成疾病的新疗法。

著录项

  • 来源
    《Nanotechnology》 |2021年第13期|共10页
  • 作者单位

    Univ Fed Rio de Janeiro Dept Clin &

    Toxicol Anal Fac Pharm Ave Carlos Chagas Filho 373 CCS Bloco A Subsolo BR-21941902 Rio De Janeiro RJ Brazil;

    Univ Fed Rio de Janeiro Dept Clin &

    Toxicol Anal Fac Pharm Ave Carlos Chagas Filho 373 CCS Bloco A Subsolo BR-21941902 Rio De Janeiro RJ Brazil;

    Univ Fed Rio de Janeiro Dept Clin &

    Toxicol Anal Fac Pharm Ave Carlos Chagas Filho 373 CCS Bloco A Subsolo BR-21941902 Rio De Janeiro RJ Brazil;

    Univ Fed Rio de Janeiro Dept Drugs &

    Pharmaceut Fac Pharm Ave Carlos Chagas Filho 373 CCS Bloco L Subsolo BR-21941902 Rio De Janeiro RJ Brazil;

    Fluminense Fed Univ Dept Organ Chem Outeiro Sao Joao Batista S-N BR-24210240 Niteroi RJ Brazil;

    Univ Fed Rio de Janeiro Dept Drugs &

    Pharmaceut Fac Pharm Ave Carlos Chagas Filho 373 CCS Bloco L Subsolo BR-21941902 Rio De Janeiro RJ Brazil;

    Univ Fed Rio de Janeiro Dept Drugs &

    Pharmaceut Fac Pharm Ave Carlos Chagas Filho 373 CCS Bloco L Subsolo BR-21941902 Rio De Janeiro RJ Brazil;

    Univ Fed Rio de Janeiro Dept Drugs &

    Pharmaceut Fac Pharm Ave Carlos Chagas Filho 373 CCS Bloco L Subsolo BR-21941902 Rio De Janeiro RJ Brazil;

    Univ Fed Rio de Janeiro Dept Clin &

    Toxicol Anal Fac Pharm Ave Carlos Chagas Filho 373 CCS Bloco A Subsolo BR-21941902 Rio De Janeiro RJ Brazil;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 特种结构材料;
  • 关键词

    hemostasis; thrombosis; rivaroxaban; pharmaceutical nanotechnology; polymeric nanoparticles;

    机译:止血;血栓形成;利伐沙班;药物纳米技术;聚合物纳米粒;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号